No Data
6-K: Report of foreign private issuer (related to financial reporting)
HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla
Express News | Takeda Plans To Host An Investor R&D Day; Expects Six Late-Stage Programs With Peak Revenue Potential Of $10B - $20B To Deliver Sustainable Growth
Takeda Pharmaceutical: To Receive Y55B From Sale of 49% Stake in JV With Teva Pharmaceutical Industries
Takeda Pharmaceutical (TAK.US) collaborates with keros therapeutics to develop innovative treatments for blood diseases.
Takeda Pharmaceutical (TAK.US) is collaborating with keros therapeutics to develop innovative therapies for blood diseases.
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Greenhorn Dav : learn from mistakes n improve...U can do it
Arrayfunction OP Greenhorn Dav : Thanks for the encouragement!
So a big thanks to anyone else out there reading this too!
One thing I forgot to mention is how much I have always appreciated the Moomoo community. I can't remember a single time I had a negative interaction with another user. Reflecting now, that played a huge role in making me feel like I belong here and kept any big loss or dumb play make me hit the eject button.
Of all the places on the internet, who would have thought it'd be a group of stock traders where everyone gets along and respects one another?
Tonyco :